See more : Capital Environment Holdings Limited (3989.HK) Income Statement Analysis – Financial Results
Complete financial analysis of GlaxoSmithKline plc (GSK.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GlaxoSmithKline plc, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Granite Creek Copper Ltd. (GCX.V) Income Statement Analysis – Financial Results
- Top Standard Corporation (8510.HK) Income Statement Analysis – Financial Results
- Enact Holdings, Inc. (ACT) Income Statement Analysis – Financial Results
- Qatar Fuel Company Q.P.S.C.(“WOQOD”) (QFLS.QA) Income Statement Analysis – Financial Results
- JJ Entertainment SE (JJSE.VI) Income Statement Analysis – Financial Results
GlaxoSmithKline plc (GSK.SW)
About GlaxoSmithKline plc
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.32B | 34.11B | 34.10B | 33.75B | 30.82B | 30.19B | 27.89B | 23.92B | 23.01B | 26.51B | 26.43B | 27.39B | 28.39B | 28.37B | 24.35B | 22.74B | 23.22B | 21.66B | 20.35B | 21.41B | 21.21B | 20.53B | 18.08B | 8.49B | 7.98B | 7.98B | 8.34B | 10.49B | 5.66B | 4.93B | 4.10B | 3.40B | 3.18B | 2.57B | 2.06B | 1.74B | 1.43B |
| Cost of Revenue | 9.55B | 11.60B | 11.70B | 11.86B | 10.24B | 10.34B | 9.29B | 8.85B | 7.32B | 8.59B | 7.89B | 7.33B | 7.59B | 7.38B | 6.42B | 5.21B | 5.01B | 4.76B | 4.31B | 4.54B | 4.61B | 4.44B | 3.96B | 4.33B | 1.55B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 19.77B | 22.51B | 22.40B | 21.89B | 20.58B | 19.84B | 18.60B | 15.07B | 15.68B | 17.92B | 18.54B | 20.06B | 20.80B | 20.99B | 17.94B | 17.53B | 18.21B | 16.89B | 16.04B | 16.88B | 16.60B | 16.09B | 14.12B | 4.16B | 6.44B | 7.98B | 8.34B | 10.49B | 5.66B | 4.93B | 4.10B | 3.40B | 3.18B | 2.57B | 2.06B | 1.74B | 1.43B |
| Gross Profit Ratio | 67.42% | 65.99% | 65.68% | 64.85% | 66.77% | 65.74% | 66.69% | 62.99% | 68.17% | 67.61% | 70.13% | 73.23% | 73.26% | 73.98% | 73.66% | 77.08% | 78.43% | 78.00% | 78.84% | 78.81% | 78.27% | 78.38% | 78.09% | 48.95% | 80.65% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 5.49B | 5.28B | 5.10B | 4.57B | 3.89B | 4.48B | 3.63B | 3.56B | 3.45B | 3.92B | 3.97B | 4.01B | 4.46B | 4.11B | 3.68B | 3.24B | 3.46B | 3.14B | 2.84B | 2.79B | 2.90B | 2.56B | 2.53B | 1.27B | 1.16B | 1.15B | 1.16B | 1.54B | 858.00M | 739.00M | 595.00M | 475.00M | 420.00M | 323.00M | 230.00M | 149.00M | 113.00M |
| General & Administrative | 8.37B | 10.98B | 11.46B | 11.40B | 9.92B | 9.67B | 9.37B | 9.23B | 8.25B | 8.48B | 8.74B | 8.83B | 13.05B | 9.59B | 7.66B | 6.82B | 7.25B | 7.25B | 7.06B | 7.57B | 8.04B | 7.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.82B | 7.26B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.37B | 10.98B | 11.46B | 11.40B | 9.92B | 9.67B | 9.37B | 9.23B | 8.25B | 8.48B | 8.74B | 8.83B | 13.05B | 9.59B | 7.66B | 13.64B | 14.51B | 7.25B | 7.06B | 7.57B | 8.04B | 7.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -523.00M | 57.00M | -383.00M | -371.00M | -292.00M | -365.00M | -421.00M | -350.00M | -319.00M | -387.00M | -336.00M | 0.00 | -493.00M | -1.14B | -541.00M | -7.55B | -7.56B | 6.14B | 0.00 | 133.28M | -1.03B | -37.16M | 8.17B | 88.00M | 2.62B | 3.94B | 4.05B | 5.38B | 2.99B | 2.67B | 2.21B | 2.92B | 2.76B | 2.25B | 1.83B | 1.59B | 1.32B |
| Operating Expenses | 13.34B | 16.31B | 16.17B | 15.60B | 13.52B | 13.78B | 12.57B | 12.44B | 11.38B | 12.02B | 12.37B | 12.84B | 17.02B | 12.56B | 10.80B | 9.33B | 10.40B | 16.53B | 9.90B | 10.49B | 9.91B | 9.99B | 10.70B | 1.36B | 3.78B | 5.08B | 5.21B | 6.92B | 3.84B | 3.41B | 2.80B | 3.40B | 3.18B | 2.57B | 2.06B | 1.74B | 1.43B |
| Cost & Expenses | 22.89B | 27.91B | 27.88B | 27.46B | 23.76B | 24.13B | 21.86B | 21.30B | 18.70B | 20.60B | 20.27B | 20.17B | 24.61B | 19.94B | 17.21B | 14.54B | 15.41B | 21.29B | 14.20B | 15.03B | 14.52B | 14.43B | 14.66B | 5.69B | 5.33B | 5.08B | 5.21B | 6.92B | 3.84B | 3.41B | 2.80B | 3.40B | 3.18B | 2.57B | 2.06B | 1.74B | 1.43B |
| Interest Income | 76.00M | 28.00M | 29.00M | 98.00M | 81.00M | 63.00M | 70.00M | 99.00M | 66.00M | 59.00M | 73.00M | 90.00M | 116.00M | 70.00M | 313.00M | 262.00M | 287.00M | 257.00M | 176.00M | 0.00 | 73.00M | 0.00 | 158.00M | 114.00M | 111.00M | 104.00M | 89.00M | 250.00M | 65.00M | 186.00M | 180.00M | 242.00M | 186.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 879.00M | 784.00M | 856.00M | 885.00M | 771.00M | 736.00M | 717.00M | 735.00M | 703.00M | 740.00M | 760.00M | 799.00M | 831.00M | 783.00M | 843.00M | 453.00M | 352.00M | 451.00M | 362.00M | 161.00M | 206.00M | 0.00 | 317.00M | 206.00M | 202.00M | 227.00M | 276.00M | 337.00M | 44.00M | 56.00M | 63.00M | 75.00M | 44.00M | 26.00M | 21.00M | 11.00M | 7.00M |
| Depreciation & Amortization | 2.30B | 2.52B | 2.35B | 2.33B | 1.86B | 1.92B | 1.77B | 1.63B | 1.48B | 1.41B | 1.45B | 1.42B | 1.68B | 1.56B | 1.23B | 1.02B | 958.04M | 903.70M | 890.48M | 859.04M | 824.00M | 812.80M | 735.00M | 428.00M | 358.00M | 373.00M | 410.00M | 533.00M | 282.00M | 225.00M | 191.00M | 151.00M | 122.00M | 93.00M | 73.00M | 55.00M | 42.00M |
| EBITDA | 18.84B | 8.04B | 9.54B | 8.82B | 7.00B | 5.55B | 4.28B | 12.94B | 5.08B | 8.61B | 8.72B | 9.72B | 5.45B | 10.10B | 8.73B | 8.92B | 9.00B | 7.96B | 7.25B | 7.23B | 6.43B | 5.56B | 6.96B | 3.19B | 3.21B | 3.27B | 3.62B | 3.20B | 2.15B | 1.95B | 1.67B | 1.47B | 1.33B | 1.12B | 931.00M | 821.00M | 658.00M |
| EBITDA Ratio | 64.25% | 23.57% | 27.97% | 26.12% | 22.72% | 18.37% | 15.35% | 54.09% | 22.08% | 32.48% | 32.98% | 35.50% | 19.19% | 35.60% | 35.86% | 39.21% | 38.75% | 36.75% | 35.64% | 33.79% | 30.29% | 27.09% | 38.50% | 37.59% | 40.22% | 40.96% | 43.35% | 30.46% | 38.00% | 39.53% | 40.84% | 43.16% | 41.84% | 43.70% | 45.22% | 47.16% | 46.05% |
| Operating Income | 16.54B | 5.52B | 7.19B | 6.48B | 5.15B | 3.62B | 2.51B | 11.31B | 3.60B | 7.20B | 7.27B | 8.30B | 3.77B | 8.54B | 7.50B | 7.89B | 8.04B | 7.05B | 6.36B | 6.38B | 5.60B | 4.75B | 6.23B | 2.76B | 2.85B | 2.90B | 3.21B | 2.66B | 1.87B | 1.72B | 1.48B | 1.32B | 1.21B | 1.03B | 858.00M | 766.00M | 616.00M |
| Operating Income Ratio | 56.41% | 16.17% | 21.07% | 19.21% | 16.70% | 12.01% | 8.99% | 47.28% | 15.63% | 27.15% | 27.52% | 30.31% | 13.27% | 30.09% | 30.81% | 34.71% | 34.63% | 32.57% | 31.26% | 29.78% | 26.41% | 23.13% | 34.44% | 32.54% | 35.74% | 36.29% | 38.44% | 25.38% | 33.01% | 34.97% | 36.18% | 38.71% | 38.00% | 40.08% | 41.67% | 44.00% | 43.11% |
| Total Other Income/Expenses | -10.91B | -73.00M | -217.00M | -262.00M | -348.00M | -99.00M | -567.00M | -785.00M | -628.00M | -548.00M | -581.00M | -602.00M | -612.00M | -645.00M | -843.00M | -356.69M | -243.28M | -323.73M | -246.26M | -55.16M | -96.00M | 1.34B | -197.00M | -188.00M | -182.00M | -210.00M | -242.00M | -275.00M | -32.00M | -49.00M | -55.00M | -32.00M | -26.00M | -24.00M | -26.00M | -20.00M | -4.00M |
| Income Before Tax | 5.63B | 5.44B | 6.97B | 6.22B | 4.80B | 3.53B | 1.94B | 10.53B | 2.97B | 6.65B | 6.69B | 7.70B | 3.16B | 7.89B | 6.66B | 7.54B | 7.80B | 6.73B | 6.12B | 6.32B | 5.51B | 6.09B | 6.03B | 2.58B | 2.67B | 2.69B | 2.96B | 2.39B | 1.84B | 1.68B | 1.43B | 1.28B | 1.18B | 1.01B | 832.00M | 746.00M | 612.00M |
| Income Before Tax Ratio | 19.19% | 15.95% | 20.43% | 18.43% | 15.57% | 11.68% | 6.95% | 44.00% | 12.90% | 25.08% | 25.32% | 28.11% | 11.12% | 27.82% | 27.34% | 33.14% | 33.58% | 31.08% | 30.05% | 29.52% | 25.96% | 29.64% | 33.35% | 30.33% | 33.46% | 33.66% | 35.54% | 22.76% | 32.44% | 33.98% | 34.84% | 37.77% | 37.18% | 39.14% | 40.41% | 42.85% | 42.83% |
| Income Tax Expense | 707.00M | 346.00M | 580.00M | 953.00M | 754.00M | 1.36B | 877.00M | 2.15B | 137.00M | 1.02B | 1.95B | 2.24B | 1.30B | 2.22B | 1.95B | 2.22B | 2.30B | 1.92B | 1.70B | 1.74B | 1.46B | 1.65B | 1.75B | 746.00M | 815.00M | 819.00M | 933.00M | 867.00M | 524.00M | 461.00M | 386.00M | 359.00M | 357.00M | 316.00M | 256.00M | 245.00M | 209.00M |
| Net Income | 4.92B | 5.10B | 6.39B | 5.27B | 4.05B | 2.17B | 1.06B | 8.37B | 2.83B | 5.63B | 4.74B | 5.46B | 1.85B | 5.67B | 4.71B | 5.32B | 5.50B | 4.81B | 4.42B | 4.58B | 4.05B | 4.43B | 4.28B | 1.83B | 1.86B | 1.87B | 2.03B | 1.52B | 1.31B | 1.21B | 1.04B | 924.00M | 825.00M | 690.00M | 576.00M | 501.00M | 403.00M |
| Net Income Ratio | 16.78% | 14.94% | 18.73% | 15.61% | 13.13% | 7.19% | 3.81% | 35.00% | 12.31% | 21.23% | 17.95% | 19.93% | 6.53% | 19.98% | 19.35% | 23.38% | 23.67% | 22.23% | 21.70% | 21.41% | 19.07% | 21.60% | 23.68% | 21.54% | 23.25% | 23.40% | 24.35% | 14.49% | 23.18% | 24.62% | 25.42% | 27.20% | 25.95% | 26.85% | 27.97% | 28.78% | 28.20% |
| EPS | 1.24 | 1.28 | 1.58 | 1.31 | 1.02 | 0.55 | 0.27 | 2.17 | 0.74 | 1.46 | 1.21 | 1.36 | 0.46 | 1.40 | 1.07 | 1.20 | 1.22 | 1.06 | 0.96 | 0.99 | 0.86 | 0.91 | 0.88 | 0.63 | 0.65 | 0.66 | 0.72 | 0.58 | 0.54 | 0.50 | 0.43 | 0.39 | 0.34 | 0.58 | 0.49 | 0.42 | 0.34 |
| EPS Diluted | 1.24 | 1.28 | 1.58 | 1.31 | 1.02 | 0.55 | 0.27 | 2.14 | 0.73 | 1.43 | 1.19 | 1.34 | 0.45 | 1.39 | 1.06 | 1.19 | 1.21 | 1.05 | 0.96 | 0.98 | 0.85 | 0.91 | 0.87 | 0.63 | 0.64 | 0.65 | 0.72 | 0.58 | 0.54 | 0.50 | 0.43 | 0.39 | 0.34 | 0.58 | 0.49 | 0.42 | 0.34 |
| Weighted Avg Shares Out | 3.98B | 3.98B | 4.03B | 4.01B | 3.98B | 3.91B | 3.89B | 3.86B | 3.85B | 3.86B | 3.93B | 4.02B | 4.07B | 4.06B | 4.42B | 4.42B | 4.51B | 4.54B | 4.59B | 4.64B | 4.73B | 4.86B | 4.85B | 2.90B | 2.88B | 2.85B | 2.82B | 2.62B | 2.43B | 2.42B | 2.41B | 2.40B | 2.40B | 1.19B | 1.18B | 1.18B | 1.18B |
| Weighted Avg Shares Out (Dil) | 3.98B | 3.98B | 4.03B | 4.01B | 3.98B | 3.95B | 3.93B | 3.91B | 3.89B | 3.94B | 3.99B | 4.08B | 4.10B | 4.09B | 4.45B | 4.45B | 4.56B | 4.58B | 4.60B | 4.67B | 4.77B | 4.90B | 4.91B | 2.91B | 2.91B | 2.88B | 2.82B | 2.62B | 2.43B | 2.42B | 2.41B | 2.40B | 2.40B | 1.19B | 1.18B | 1.18B | 1.18B |
Source: https://incomestatements.info
Category: Stock Reports